Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No English Funding For Lymphoma Drugs Ledaga and Poteligeo

Issues With Clinical Trial Design Among Issues Of Concern To HTA Body NICE

Executive Summary

Limitations in the design of the clinical trials that were carried out for each drug are among the concerns highlighted by the health technology assessment body in two interim guidances that are now out for consultation.

You may also be interested in...



Advanced Therapies From Orchard & Kite Win EMA Thumbs Up

Novartis’s siRNA for lowering cholesterol was also among the 10 new medicines that the European Medicines Agency this week said should be approved in the EU.

Bayer Seeks Speedy EMA Review For Diabetic Kidney Disease Drug Finerenone

The developers of three drugs are hoping the European Medicines Agency will decide that their products merit fast-tracking when they are submitted for review for potential pan-EU approval.

Brexit: MHRA Joins Second International Work-Sharing Scheme To Speed Up Drug Approvals

Hot on the heels of announcing it was joining Project Orbis, the UK drug regulator, the MHRA, now says it will join another international collaboration that allows drug companies to submit medicines for review by several countries at the same time.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel